A recent research
conducted by Future Market Insights predicts that the global market
for branded generics will witness a steady growth in terms of
revenues. Over a ten-year forecast period from 2016 to 2026, the size
of global branded generics market has been estimated to expand at a
steady CAGR of 7.3%. Brand-name prescriptions will continue to be
ubiquitous among aged people in the world, and since geriatric
demographics account for a large portion of global drug-consuming
population, demand for branded generics will also rise substantially.
In 2016, the global branded generics market has been valued at nearly
US$ 200 billion, and is projected to reach US$ 413.8 Bn market value
by the end of forecast period.
Read Report
Overview @
https://www.futuremarketinsights.com/reports/branded-generics-market
Some of the leading
manufacturers of branded generics are based in Asian countries, and
are extending their production capacity to keep up with the surging
global depend. In Asia-Pacific excluding Japan (APEJ) region, about
US$ 150 billion revenues are expected to be procured by the end of
2026. During the forecast period, branded generics market in the APEJ
region will attain fastest growth, registering a 10% CAGR,
contributing over 35% of global branded generics revenues. North
America, Eastern Europe and Latin America are also expected to be
lucrative for growth of branded generics sales, while revenues in
Western Europe, Japan and Middle East & Africa (MEA) are likely
to incur a considerable dip by 2026-end.
Since 2015, Abbott
Laboratories, a leading drugmaker in the global pharmaceuticals
industry, has aimed at capitalizing from branded generics businesses
in developing regions. Teva Pharmaceuticals acquired Allergan’s
branded generics vertical, while Pfizer Inc. bought Hospira Inc. –
both acquisitions have been strategically carried out for
repositioning market standings of Teva and Pfizer respectively. In
December 2016, India-based Sun Pharmaceuticals Industries Ltd. agreed
to buy Swiss drugmaker Novartis AG’s branded generics portfolio on
cancer medications.
Request Sample
Report @
https://www.futuremarketinsights.com/reports/sample/rep-gb-1260
Nearly three-fifth
of the global branded generics revenues estimated in 2016 are
expected to be accounted by oral-type formulations, with parenteral,
topic and other formulation types collectively accounting for 8%
market value share. Hospital pharmacies & retail pharmacies will
remain as the largest distribution channels for branded generics
throughout the globe.
In 2016 and beyond,
the demand for branded generics in therapeutic treatment of
cardiovascular diseases will be significant, revenues from which are
expected to increase at more than 8% CAGR over the forecast period.
Global revenues of
branded generics accounted by anti-hypertensive drug class are
predicted to surpass US$ 25 billion by 2026-end.As per Future Market
Insights analysis, emerging economics such as Brazil, Russia, India
and China are the most lucrative markets for branded generics. A big
aspect that is fuelling the global branded generics market is the
increasing out-of-pocket expenditure on healthcare in both emerging
and developed economies. In addition, patent expiries of blockbuster
drugs is also positively impacting the global branded generics
market. Analysts working on this report have noticed a trend of
mergers and acquisitions amongst the key market players to help
consolidate their position in the global branded generics market.
Buy Full Branded
Generics Market Report @
https://www.futuremarketinsights.com/checkout/1260
CONTACT:
Future Market
Insights
616 Corporate Way,
Suite 2-9018,
Valley Cottage, NY
10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email:
sales@futuremarketinsights.com
Website:
www.futuremarketinsights.com
No comments:
Post a Comment